Handa Pharmaceuticals Financials
| 6620 Stock | TWD 73.70 3.40 4.41% |
Handa |
Understanding current and past Handa Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Handa Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Handa Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Handa Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Handa Pharmaceuticals. Check Handa Pharmaceuticals' Beneish M Score to see the likelihood of Handa Pharmaceuticals' management manipulating its earnings.
Handa Pharmaceuticals Stock Summary
Handa Pharmaceuticals competes with Lotus Pharmaceutical, Synmosa Biopharma, GeneFerm Biotechnology, and Alar Pharmaceuticals. Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company also develops modified release dosage forms, such as orally disintegrating tablets, modified release orally disintegrating tablets, modified release suspension systems, and ophthalmic modified release systems. HANDA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan OTC Exchange |
| Business Address | No23, Nanke 3rd |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.handapharma.com.tw |
| Phone | 886 6 505 7508 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in Handa Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Handa Stock, because this is throwing your money away. Analyzing the key information contained in Handa Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Handa Pharmaceuticals Key Financial Ratios
There are many critical financial ratios that Handa Pharmaceuticals' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Handa Pharmaceuticals reports annually and quarterly.| Return On Equity | -41.47 | |||
| Return On Asset | -27.2 | |||
| Beta | 1.31 |
Handa Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Handa Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Handa Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Handa Pharmaceuticals competition to find correlations between indicators driving Handa Pharmaceuticals's intrinsic value. More Info.Handa Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Handa Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Handa Pharmaceuticals Systematic Risk
Handa Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Handa Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Handa Pharmaceuticals correlated with the market. If Beta is less than 0 Handa Pharmaceuticals generally moves in the opposite direction as compared to the market. If Handa Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Handa Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Handa Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Handa Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Handa Pharmaceuticals December 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Handa Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Handa Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Handa Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Handa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Handa Pharmaceuticals's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.25 | |||
| Information Ratio | 0.0278 | |||
| Maximum Drawdown | 18.46 | |||
| Value At Risk | (3.82) | |||
| Potential Upside | 6.98 |
Additional Tools for Handa Stock Analysis
When running Handa Pharmaceuticals' price analysis, check to measure Handa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Handa Pharmaceuticals is operating at the current time. Most of Handa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Handa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Handa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Handa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.